Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
NCT05925413
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
41
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Cadonilimab+TACE
Sponsor
Eastern Hepatobiliary Surgery Hospital